236 related articles for article (PubMed ID: 21387276)
1. Impact of body mass index on clinical outcomes in triple-negative breast cancer.
Ademuyiwa FO; Groman A; O'Connor T; Ambrosone C; Watroba N; Edge SB
Cancer; 2011 Sep; 117(18):4132-40. PubMed ID: 21387276
[TBL] [Abstract][Full Text] [Related]
2. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.
Dignam JJ; Polite BN; Yothers G; Raich P; Colangelo L; O'Connell MJ; Wolmark N
J Natl Cancer Inst; 2006 Nov; 98(22):1647-54. PubMed ID: 17105987
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of body mass index in locally advanced breast cancer.
Dawood S; Broglio K; Gonzalez-Angulo AM; Kau SW; Islam R; Hortobagyi GN; Cristofanilli M
Clin Cancer Res; 2008 Mar; 14(6):1718-25. PubMed ID: 18347172
[TBL] [Abstract][Full Text] [Related]
4. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle.
Wolters R; Schwentner L; Regierer A; Wischnewsky M; Kreienberg R; Wöckel A
Breast Cancer Res Treat; 2012 Feb; 131(3):925-31. PubMed ID: 22080246
[TBL] [Abstract][Full Text] [Related]
5. Does obesity have an effect on outcomes in triple-negative breast cancer?
Mowad R; Chu QD; Li BD; Burton GV; Ampil FL; Kim RH
J Surg Res; 2013 Sep; 184(1):253-9. PubMed ID: 23768767
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.
Lara-Medina F; Pérez-Sánchez V; Saavedra-Pérez D; Blake-Cerda M; Arce C; Motola-Kuba D; Villarreal-Garza C; González-Angulo AM; Bargalló E; Aguilar JL; Mohar A; Arrieta Ó
Cancer; 2011 Aug; 117(16):3658-69. PubMed ID: 21387260
[TBL] [Abstract][Full Text] [Related]
7. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
[TBL] [Abstract][Full Text] [Related]
9. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Fisher B; Jeong JH; Anderson S; Wolmark N
J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
[TBL] [Abstract][Full Text] [Related]
10. Obesity and outcomes in premenopausal and postmenopausal breast cancer.
Loi S; Milne RL; Friedlander ML; McCredie MR; Giles GG; Hopper JL; Phillips KA
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1686-91. PubMed ID: 16030102
[TBL] [Abstract][Full Text] [Related]
11. The obesity paradox: body mass index and outcomes in patients with heart failure.
Curtis JP; Selter JG; Wang Y; Rathore SS; Jovin IS; Jadbabaie F; Kosiborod M; Portnay EL; Sokol SI; Bader F; Krumholz HM
Arch Intern Med; 2005 Jan; 165(1):55-61. PubMed ID: 15642875
[TBL] [Abstract][Full Text] [Related]
12. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.
Meyerhardt JA; Catalano PJ; Haller DG; Mayer RJ; Benson AB; Macdonald JS; Fuchs CS
Cancer; 2003 Aug; 98(3):484-95. PubMed ID: 12879464
[TBL] [Abstract][Full Text] [Related]
13. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation.
Navarro WH; Loberiza FR; Bajorunaite R; van Besien K; Vose JM; Lazarus HM; Rizzo JD
Biol Blood Marrow Transplant; 2006 May; 12(5):541-51. PubMed ID: 16635789
[TBL] [Abstract][Full Text] [Related]
14. 'Weighing in' on screening mammography.
Berz D; Sikov W; Colvin G; Weitzen S
Breast Cancer Res Treat; 2009 Apr; 114(3):569-74. PubMed ID: 18491226
[TBL] [Abstract][Full Text] [Related]
15. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
16. Impact of a raised body mass index on breast cancer survival in relation to age and disease extent at diagnosis.
Imkampe AK; Bates T
Breast J; 2010; 16(2):156-61. PubMed ID: 19968656
[TBL] [Abstract][Full Text] [Related]
17. Body mass and mortality after breast cancer diagnosis.
Whiteman MK; Hillis SD; Curtis KM; McDonald JA; Wingo PA; Marchbanks PA
Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):2009-14. PubMed ID: 16103453
[TBL] [Abstract][Full Text] [Related]
18. Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes.
Eisenstein EL; McGuire DK; Bhapkar MV; Kristinsson A; Hochman JS; Kong DF; Califf RM; Van de Werf F; Yancy WS; Newby LK
Am J Med; 2005 Sep; 118(9):981-90. PubMed ID: 16164884
[TBL] [Abstract][Full Text] [Related]
19. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
Meyerhardt JA; Tepper JE; Niedzwiecki D; Hollis DR; McCollum AD; Brady D; O'Connell MJ; Mayer RJ; Cummings B; Willett C; Macdonald JS; Benson AB; Fuchs CS
J Clin Oncol; 2004 Feb; 22(4):648-57. PubMed ID: 14966087
[TBL] [Abstract][Full Text] [Related]
20. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
Modesitt SC; Tian C; Kryscio R; Thigpen JT; Randall ME; Gallion HH; Fleming GF;
Gynecol Oncol; 2007 Apr; 105(1):59-65. PubMed ID: 17150247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
